Latest From Ixchelsis Ltd.
With backing from Bayer and others, the US-based venture will develop iPSC therapies for cardiovascular and neurodegenerative diseases; other notable new financings involve Cerevance, Goldfinch Bio, NeuroPharma and Tenaya. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced November through December 2016.
It’s the 10th anniversary of START-UP’s A-List, an analysis of the year’s Series A life science funding, and a highlight of the year’s most interesting new companies. Deal flow was up this year, as was the average disclosed amount of financing.
The U.K. biotech aims to transform the biologics market with its first-in-class human antibody-fragment technology, with mild to moderate psoriasis the lead therapeutic target.
As part of a new R&D investment approach, Eli Lilly has partnered with TVM Capital and HealthCare Ventures, which have raised $250 million and funded the start of eight single-molecule companies. Corporate Business Development VP Darren Carroll discussed how the company’s venture initiative has evolved during Elsevier’s Pharmaceutical Strategic Alliance conference Sept. 25.
- Therapeutic Areas
- Gynecological, Urological
- Western Europe
- Parent & Subsidiaries
- Ixchelsis Ltd.
- Senior Management
Gary Muirhead, CEO
Ian Osterloh, CMO
- Contact Info
Discovery Park House
Sandwich, CT13 9NJ
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.